Cagrilintide is an amylin-analog, now being developed in combination with the Canaglitide is a novel long-acting acylated amylin analogue that acts as a non-selective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Caglilin can significantly reduce weight and reduce food intake. Canagorelin tide has potential in obesity research.